Literature DB >> 21251905

Consistent interactions between tumor cell IL-6 and macrophage TNF-α enhance the growth of human prostate cancer cells in the bone of nude mouse.

Seung Wook Kim1, Jang Seong Kim, John Papadopoulos, Hyun Jin Choi, Junqin He, Marva Maya, Robert R Langley, Dominic Fan, Isaiah J Fidler, Sun-Jin Kim.   

Abstract

To test the hypothesis that tumor-associated macrophages (TAMs) enhance the growth and metastasis of human prostate cancer in the bone, we evaluated the effects of decreasing interleukin-6 (IL-6) production by tumor cells and TAMs in a mouse model of bone metastasis. Human PC-3MM2 cells that produce IL-6 were transfected with lentivirus containing IL-6 small hairpin RNA (shRNA) or nonspecific RNA and injected into the tibias of nude mice treated intraperitoneally every 5days for 5weeks with phosphate-buffered saline (PBS), liposomes containing PBS, or liposomes containing clodronate (to decrease the number of macrophages). Transfection of PC-3MM2 cells with IL-6 shRNA significantly decreased cellular expression of IL-6 and the number of TAMs and osteoclasts in bone tumors, which correlated with significant decreases in tumor size, bone lysis, and incidence of lymph node metastasis. Treatment of mice with clodronate liposomes significantly decreased the number of TAMs and osteoclasts in the bone tumors, the expression of IL-6 in the PC3-MM2 cells, and the production of tumor necrosis factor (TNF)-α by TAMs. These findings correlated with a significant decrease in tumor size, bone lysis, and lymph node metastasis. Knocking down IL-6 in tumor cells and decreasing TAMs was associated with the lowest incidences of bone tumors and lymph node metastasis. These results suggest that TAMs enhance the growth of prostate cancer cells in the bone.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21251905      PMCID: PMC3086935          DOI: 10.1016/j.intimp.2011.01.004

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  57 in total

1.  Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma.

Authors:  H L Adler; M A McCurdy; M W Kattan; T L Timme; P T Scardino; T C Thompson
Journal:  J Urol       Date:  1999-01       Impact factor: 7.450

2.  Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine.

Authors:  Monique B Nilsson; Robert R Langley; Isaiah J Fidler
Journal:  Cancer Res       Date:  2005-12-01       Impact factor: 12.701

3.  IL-6, M-CSF and IAP cytokines in ovarian cancer: simultaneous assessment of serum levels.

Authors:  E Foti; G Ferrandina; R Martucci; M E Romanini; P Benedetti Panici; U Testa; S Mancuso; G Scambia
Journal:  Oncology       Date:  1999-10       Impact factor: 2.935

4.  Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer.

Authors:  Sun-Jin Kim; Hisanori Uehara; Sertac Yazici; Junqin He; Robert R Langley; Paul Mathew; Dominic Fan; Isaiah J Fidler
Journal:  Cancer Res       Date:  2005-05-01       Impact factor: 12.701

Review 5.  Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment.

Authors:  K S Koeneman; F Yeung; L W Chung
Journal:  Prostate       Date:  1999-06-01       Impact factor: 4.104

6.  Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer.

Authors:  D E Drachenberg; A A Elgamal; R Rowbotham; M Peterson; G P Murphy
Journal:  Prostate       Date:  1999-10-01       Impact factor: 4.104

7.  Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth.

Authors:  Shintaro Nakao; Takashi Kuwano; Chikako Tsutsumi-Miyahara; Shu-ichi Ueda; Yusuke N Kimura; Shinjiro Hamano; Koh-hei Sonoda; Yasuo Saijo; Toshihiro Nukiwa; Robert M Strieter; Tatsuro Ishibashi; Michihiko Kuwano; Mayumi Ono
Journal:  J Clin Invest       Date:  2005-10-20       Impact factor: 14.808

8.  Interleukin-6-mediated autocrine growth promotion in human glioblastoma multiforme cell line U87MG.

Authors:  S Goswami; A Gupta; S K Sharma
Journal:  J Neurochem       Date:  1998-11       Impact factor: 5.372

9.  Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice.

Authors:  C A Pettaway; S Pathak; G Greene; E Ramirez; M R Wilson; J J Killion; I J Fidler
Journal:  Clin Cancer Res       Date:  1996-09       Impact factor: 12.531

10.  Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma.

Authors:  T Nakano; A P Chahinian; M Shinjo; A Tonomura; M Miyake; N Togawa; K Ninomiya; K Higashino
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

View more
  20 in total

Review 1.  Tumor-associated macrophages: functional diversity, clinical significance, and open questions.

Authors:  Subhra K Biswas; Paola Allavena; Alberto Mantovani
Journal:  Semin Immunopathol       Date:  2013-05-09       Impact factor: 9.623

Review 2.  Integrating new discoveries into the "vicious cycle" paradigm of prostate to bone metastases.

Authors:  Leah M Cook; Gemma Shay; Arturo Araujo; Arturo Aruajo; Conor C Lynch
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

3.  Murine mesothelioma induces locally-proliferating IL-10(+)TNF-α(+)CD206(-)CX3CR1(+) M3 macrophages that can be selectively depleted by chemotherapy or immunotherapy.

Authors:  Connie Jackaman; Teong L Yeoh; Manyual L Acuil; Joanne K Gardner; Delia J Nelson
Journal:  Oncoimmunology       Date:  2016-04-22       Impact factor: 8.110

Review 4.  Current treatments and novel therapeutic targets for castration resistant prostate cancer with bone metastasis.

Authors:  Juncheng Wei; Zhilin Wang; Danil Makarov; Xin Li
Journal:  Am J Clin Exp Urol       Date:  2013-12-25

5.  Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer.

Authors:  Windy Dean-Colomb; Kenneth R Hess; Elliana Young; Terrie G Gornet; Beverly C Handy; Stacy L Moulder; Nuhad Ibrahim; Lajos Pusztai; Daniel Booser; Vicente Valero; Gabriel N Hortobagyi; Francisco J Esteva
Journal:  Breast Cancer Res Treat       Date:  2012-12-15       Impact factor: 4.872

Review 6.  Understanding and targeting osteoclastic activity in prostate cancer bone metastases.

Authors:  J L Sottnik; E T Keller
Journal:  Curr Mol Med       Date:  2013-05       Impact factor: 2.222

7.  Marine- and plant-derived ω-3 fatty acids differentially regulate prostate cancer cell proliferation.

Authors:  Pinar O Eser; John P Vanden Heuvel; John Araujo; Jerry T Thompson
Journal:  Mol Clin Oncol       Date:  2013-02-15

Review 8.  Nanotechnology in the targeted drug delivery for bone diseases and bone regeneration.

Authors:  Wenyi Gu; Chengtie Wu; Jiezhong Chen; Yin Xiao
Journal:  Int J Nanomedicine       Date:  2013-06-25

Review 9.  The Role of Inflammation in Breast and Prostate Cancer Metastasis to Bone.

Authors:  Andy Göbel; Stefania Dell'Endice; Nikolai Jaschke; Sophie Pählig; Amna Shahid; Lorenz C Hofbauer; Tilman D Rachner
Journal:  Int J Mol Sci       Date:  2021-05-11       Impact factor: 5.923

10.  Bisphosphonates and cancer: what opportunities from nanotechnology?

Authors:  Giuseppe De Rosa; Gabriella Misso; Giuseppina Salzano; Michele Caraglia
Journal:  J Drug Deliv       Date:  2013-03-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.